GlassScriptPhysician profile
Alejandro A Magadan
NPI 1659521565
$722.91
in general payments reported to CMS, 2019-2025
11 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.85 · 2021: $33.03 · 2022: $207 · 2023: $66.26 · 2024: $188 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $151.33 | 2023-2025 | |
| Amgen INC. | $142.36 | 2025 | Uplizna |
| Omniscient Neurotechnology America LTD | $126.00 | 2022 | |
| Ucb, INC. | $115.31 | 2020-2022 | |
| Pfizer INC. | $73.38 | 2023-2024 | |
| W. L. Gore & Associates, INC. | $30.69 | 2024 | Gore Cardioform Septal Occluder |
| Novartis Pharmaceuticals Corporation | $22.14 | 2024 | |
| Life Molecular Imaging LTD | $20.29 | 2024 | Neuraceq |
| Janssen Pharmaceuticals, INC | $15.35 | 2022 | |
| Ge Healthcare | $14.23 | 2024 | |
| Xeris Pharmaceuticals, INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Magadan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.